|Bid||64.39 x 800|
|Ask||64.40 x 800|
|Day's range||63.25 - 64.46|
|52-week range||53.22 - 69.75|
|Beta (5Y monthly)||0.63|
|PE ratio (TTM)||N/A|
|Earnings date||04 Feb 2022|
|Forward dividend & yield||2.16 (3.47%)|
|Ex-dividend date||06 Jan 2022|
|1y target est||72.22|
PRINCETON, N.J., January 28, 2022--BMS Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory DLBCL, PMBCL and FL3B
Dividend stocks are worth serious consideration, especially given the current state of the economy. Let's look at two companies to consider -- both of which are excellent, dividend-paying companies and look like steals at current levels: AbbVie (NYSE: ABBV) and Bristol Myers Squibb (NYSE: BMY). Pharma giant AbbVie offers a dividend yield of 4.01%, significantly higher than the S&P 500's average of 1.27%.
Genomic sequencing leader Illumina (NASDAQ: ILMN) recently provided guidance for 2022 and revealed some of its plans for the year. In this Motley Fool Live video, recorded on Jan. 12, Fool contributors Keith Speights and Brian Orelli discuss the outlook for Illumina going forward. Keith Speights: Hey, there's a company that you and I haven't talked about very much, at least, I'm going to say at least over the last seven or eight months and maybe longer than that.